0000000000682128

AUTHOR

Francesco Cipollone

showing 21 related works from this author

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST tria…

2010

Introduction: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ)12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients…

MaleSystolic hypertensionOffice VisitsPharmacologySeverity of Illness Indexlaw.inventionHydrochlorothiazideRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerPharmacology (medical)DiureticsImidazolesGeneral MedicineBlood Pressure Monitoring AmbulatoryAntihypertensive AgentLosartanHydrochlorothiazideTreatment OutcomeAcrylatesHypertensionCardiologyDrug Therapy CombinationFemaleDrug MonitoringHumanmedicine.drugmedicine.medical_specialtyAmbulatory blood pressureSystoleLosartan/hydrochlorothiazideThiopheneselderly patientselderlyLosartanStatistics NonparametricDouble-Blind MethodThiopheneInternal medicinemedicineDiureticHumansImidazoleAntihypertensive AgentsAgedAnalysis of Variancebusiness.industryeprosartanEprosartanmedicine.diseaseambulatory blood pressure monitoringAcrylateBlood pressureOffice VisitbusinessAngiotensin II Type 1 Receptor BlockersAdvances in therapy
researchProduct

What changed in the Italian internal medicine and geriatric wards during the lockdown

2021

A total of 48 internal medicine or geriatric wards among the 93 adhering to the register REPOSI answered an online questionnaire aimed to investigate the characteristics and activities of converted and non-converted wards in the crucial period of the first wave of the epidemic, 22 February-4 May 2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Aged; Humans; Italy; Hospitals; Internal MedicineMEDLINEgeriatricSocio-culturalelaw.inventionlockdownHospitalPatient TransportlawPandemicHospital dischargemedicineInternal MedicineAged Hospitals Humans Internal Medicine ItalyHumansLetter to the EditorInternal medicineAgedLS7_9business.industrygeriatric patientsmedicine.diseaseIntensive care unitHospitalsInternal medicine geriatric patients lockdown covid-19Italycovid-19Medical emergencybusinessHuman
researchProduct

Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. T…

2017

Background Type 2 diabetes mellitus (T2DM) is one of the most common causes of chronic kidney disease and kidney failure. It has been estimated that the annual decline of estimated glomerular filtration rate (eGFR) among patients with T2DM is approximately 2.0-2.5 mL min−1 y−1. Cyclooxygenase-dependent eicosanoids, such as 11-dehydro-thromboxane (Tx)B2, are increased in T2DM patients and are potentially involved in the regulation of renal blood flow. Animal models showed that cyclooxygenase inhibitors, such as aspirin, are associated with improvements in renal plasma flow and eGFR values. Hypothesis The primary end point of the LEDA trial is to evaluate the 1-year decline of eGFR in T2DM pa…

Time Factorskidney disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineRenal Insufficiency030212 general & internal medicineChronicKidneyAspirinkidney disease progressionclinical trialtrialPrognosisType 2 diabetes mellituAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus Type 2; Disease Progression; Dose-Response Relationship Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency Chronic; Time Factors; Cardiology and Cardiovascular Medicinemedicine.anatomical_structureAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus; Type 2; Disease Progression; Dose-Response Relationship; Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency; Chronic; Time Factors; Cardiology and Cardiovascular MedicineDisease Progressiontype 2 diabetesDrugSettore SECS-S/01 - StatisticaCardiology and Cardiovascular MedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyUrologyRenal functionDose-Response Relationship03 medical and health sciencesDouble-Blind MethodDiabetes MellitusHumansCyclooxygenase InhibitorsRenal Insufficiency Chronickidney disease kidney disease progression type 2 diabetes aspirin trialDose-Response Relationship DrugAspirinbusiness.industryrenal functionmedicine.diseaseSurgeryClinical trialDiabetes Mellitus Type 2Renal blood flowbusinessFollow-Up StudiesKidney disease
researchProduct

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

2023

: Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and Results An lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause …

cardiovascular risklipoprotein(a).familial hypercholesterolemia
researchProduct

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

2021

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Dat…

MaleSettore MED/09 - Medicina InternaArterial diseaseCross-sectional studyAdult populationCoronary DiseaseDiseaseGlobal HealthMedical and Health SciencesDoenças Cardio e Cérebro-vascularesAnticholesteremic AgentMonoclonalPrevalenceRegistriesFamilial HypercholesterolemiaHumanizedStroke11 Medical and Health SciencesLS2_9Studies CollaborationAnticholesteremic AgentsGeneral MedicineHeart Disease Risk FactorMiddle AgedFHSC global registry dataEuropeTreatment OutcomeLower prevalenceGuidancelipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Familial hypercholesterolaemiaLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyCombination therapyFHSC global registry heterozygous familial hypercholesterolaemiaCardiovascular risk factorsAntibodies Monoclonal HumanizedInsightsAntibodiesNOHyperlipoproteinemia Type IIClinicianMedicine General & InternalInternal medicineGeneral & Internal MedicineHealth SciencesmedicineHumansEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)Cross-Sectional StudieScience & TechnologyGlobal Perspectivebusiness.industryCholesterol LDLmedicine.diseaseCross-Sectional StudiesHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

2019

Abstract Objectives We aimed to analyze the prevalence and impact of COPD in older patients hospitalized in internal medicine or geriatric wards, and to investigate adherence to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, associated clinical factors, and outcomes. Design Data were obtained from REgistro POliterapie SIMI (REPOSI), a prospective multicenter observational registry that enrolls inpatients aged ≥65 years. Setting and Participants Older hospitalized patients enrolled from 2008 to 2016 with a diagnosis of COPD. Measures We evaluated adherence to the 2018 GOLD guidelines at admission and discharge, by examining the prescription of inhaled bronchodi…

Malemajor clinical eventmajor clinical eventsPulmonary Disease Chronic Obstructive0302 clinical medicineOlder patientsAdrenal Cortex Hormones80 and over030212 general & internal medicineLS4_4adherenceProspective StudiesGeneral NursingNursing (all)2901 Nursing (miscellaneous)Aged 80 and overCOPDHealth PolicyGeneral MedicineCOPD guidelines adherence major clinical events older patientsolder patientsObstructive lung diseaseBronchodilator Agentsguidelines adherenceHospitalizationInhalationCOPD; guidelines adherence; major clinical events; older patients; Administration Inhalation; Adrenal Cortex Hormones; Aged; Aged 80 and over; Bronchodilator Agents; Female; Humans; Male; Prospective Studies; Pulmonary Disease Chronic Obstructive; Guideline Adherence; HospitalizationAdministrationFemaleGuideline AdherenceCOPD guidelinesCOPD; guidelines adherence; major clinical events; older patients; Nursing (all)2901 Nursing (miscellaneous); Health Policy; Geriatrics and GerontologyChronic Obstructivemedicine.medical_specialtySocio-culturalePulmonary Disease03 medical and health sciencesolder patientInternal medicineAdministration InhalationmedicineHumansCOPDMedical prescriptionAgedPolypharmacybusiness.industrySettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseConfidence intervalrespiratory tract diseasesCOPD; guidelines adherence; major clinical events; older patientsObservational studyGeriatrics and Gerontologybusiness030217 neurology & neurosurgery
researchProduct

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian…

2020

Abstract Background Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatme…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLower risklaw.inventionCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality; Aged; Aged 80 and over; COVID-19; Female; Hospital Mortality; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; Treatment OutcomeCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality03 medical and health sciences0302 clinical medicineRandomized controlled trialRetrospective StudielawInternal medicine80 and overInternal MedicinemedicineHumans030212 general & internal medicineHospital MortalityMortalityRisk factorDisease severityAgedRetrospective StudiesInflammationAged 80 and overbusiness.industryMortality rateCOVID-19HydroxychloroquineRetrospective cohort studyMiddle AgedCOVID-19 Drug TreatmentTreatment OutcomeItalyPropensity score matchingCommentaryObservational studyFemalebusinessHumanmedicine.drugHydroxychloroquineEuropean journal of internal medicine
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings f…

2020

Background and aims There is poor knowledge on characteristics, comorbidities and laboratory measures associated with risk for adverse outcomes and in-hospital mortality in European Countries. We aimed at identifying baseline characteristics predisposing COVID-19 patients to in-hospital death. Methods and results Retrospective observational study on 3894 patients with SARS-CoV-2 infection hospitalized from February 19th to May 23rd, 2020 and recruited in 30 clinical centres distributed throughout Italy. Machine learning (random forest)-based and Cox survival analysis. 61.7% of participants were men (median age 67 years), followed up for a median of 13 days. In-hospital mortality exhibited a…

MaleEpidemiologyEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologycomputer.software_genreMachine Learning0302 clinical medicineRetrospective StudieRisk FactorsCardiovascular DiseaseEpidemiology80 and overMedicineAge FactorViralHospital MortalityBetacoronavirus Hospital MortalityYoung adultAged 80 and overNutrition and DieteticsCOVID-19; Epidemiology; In-hospital mortality; Risk factorsMortality rateHazard ratioAge FactorsMiddle AgedIn-hospital mortalityC-Reactive ProteinCardiovascular DiseasesFemaleSurvival AnalysiCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentPneumonia Viral030209 endocrinology & metabolismSettore MED/17 - MALATTIE INFETTIVEMachine learningCOVID-19; Epidemiology; In-hospital mortality; Risk factors; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; C-Reactive Protein; COVID-19; Cardiovascular Diseases; Coronavirus Infections; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pandemics; Pneumonia Viral; Retrospective Studies; Risk Factors; SARS-CoV-2; Survival Analysis; Young Adult; Betacoronavirus; Hospital Mortality; Machine LearningArticle03 medical and health sciencesBetacoronavirusYoung AdultHumansRisk factorPandemicsSurvival analysisAgedRetrospective StudiesPandemicBetacoronavirubusiness.industryCoronavirus InfectionSARS-CoV-2Risk FactorCOVID-19Retrospective cohort studyPneumoniaSurvival AnalysisConfidence intervalRisk factorsArtificial intelligencebusinesscomputerNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Lopinavir/ritonavir and darunavir/cobicistat in hospitalized covid-19 patients: Findings from the multicenter italian corist study

2021

Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients.Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of…

Medicine (General)medicine.medical_specialtyLopinavir/ritonavirLopinavirR5-920Internal medicinemedicineDarunavirOriginal ResearchCOVID-19; Darunavir; In-hospital mortality; Lopinavir; SARS-CoV-2DarunavirCOVID-19; SARS-CoV-2; darunavir; in-hospital mortality; lopinavirbusiness.industrySARS-CoV-2CobicistatMortality rateCOVID-19LopinavirGeneral Medicinemedicine.diseaseIn-hospital mortalityPropensity score matchingMedicineRitonavirbusinessmedicine.drugKidney disease
researchProduct

Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Stud…

2013

Primary aldosteronism (PA) is the most common endocrine form of hypertension and may carry an increased risk of atrial flutter or fibrillation (AFF). The primary goal of this multicentre cohort study is thus to prospectively establish the prevalence of PA in consecutive hypertensive patients referred for lone (non-valvular), paroxysmal or permanent AFF. Secondary objectives are to determine: (1) the predictors of AFF in patients with PA; (2) the rate of AFF recurrence at follow-up after specific treatment in the patients with PA; (3) the effect of AFF that can increase atrial natriuretic peptide via the atrial stretch and thereby blunt aldosterone secretion, on the aldosterone-to-renin rati…

medicine.medical_specialtyTime FactorsTime FactorElectric CountershockPlasma renin activityaldosteronism; atrial fibrillation; high blood pressure; plasma reninPrimary aldosteronismRecurrenceInternal medicineatraial fibrillationReninHyperaldosteronismInternal MedicinePrevalenceMedicineHumansSinus rhythmatrial fibrillationprimary aldosteronism; hypertension; atraial fibrillationProspective StudiesProspective cohort studyAldosteroneFibrillationaldosteronismprimary aldosteronismChi-Square Distributionbusiness.industryAtrial fibrillationmedicine.diseaseHyperaldosteronismplasma reninEuropeProspective StudieTreatment OutcomeAtrial FlutterResearch DesignAnti-Arrhythmia AgentBiological MarkerHypertensionCardiologyQuality of Lifemedicine.symptombusinessAnti-Arrhythmia AgentsAtrial flutterBiomarkersHumanhigh blood pressure
researchProduct

A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.

2022

ODYSSEY APPRISE trial evaluated efficacy and safety of alirocumab in 994 patients with hypercholesterolemia and high CV risk in a real-life setting. The aim of the present report is to detail on the Italian cohort enrolled and treated in the trial.The methodology of the of the multinational, single-arm, Phase 3b open-label ODYSSEY APPRISE (Clinicaltrials.gov: NCT02476006) has been previously reported. 255 Italian patients were enrolled and treated according to the trial protocol. Overall mean exposure to alirocumab was 83.3 ± 27.7 weeks. At week 12, LDL-C decreased by 51.3 ± 23.1% and this reduction was overall maintained for the duration of the study. A similar reduction was observed in pa…

Settore MED/09 - Medicina InternaNutrition and DieteticsLDL-C.Endocrinology Diabetes and MetabolismAnticholesteremic AgentsMedicine (miscellaneous)alirocumabCholesterol LDLAntibodies Monoclonal HumanizedHyperlipoproteinemia Type IIheterozygous familial hypercholesterolemiaTreatment OutcomeItalyHumansheterozygous familial hypercholesterolemia; high cardiovascular risk; alirocumab; LDL-C; Italyhigh cardiovascular riskCardiology and Cardiovascular MedicineLDL-CNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering

2021

The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and experimental studies reporting contrasting results. To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February–May 2020). Patients’ characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases, and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distan…

MaleMedicine (General)Antimalarial030204 cardiovascular system & hematologySeverity of Illness IndexHospital Mortality.0302 clinical medicineRetrospective Studie80 and overCluster Analysis030212 general & internal medicineHospital MortalityAged; Aged 80 and over; Antimalarials; COVID-19; Cluster Analysis; Female; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Hospital MortalityAged 80 and overMiddle AgedTreatment OutcomeItalyFemaleBiotechnologymedicine.drugResearch ArticleHydroxychloroquinemedicine.medical_specialtyArticle SubjectBiomedical EngineeringRenal functionHealth Informatics03 medical and health sciencesAntimalarialsR5-920Internal medicineDiabetes mellitusSeverity of illnessmedicineMedical technologyHumansR855-855.5AgedRetrospective StudiesCluster Analysibusiness.industrySARS-CoV-2CancerCOVID-19Retrospective cohort studyHydroxychloroquinemedicine.diseaseObesityCOVID-19 Drug TreatmentSurgeryObservational studybusinessJournal of Healthcare Engineering
researchProduct

Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients.

2019

Depression is often under-recognized in older patients, even if antidepressants (AD) are commonly prescribed, with a prevalence of use that increase with ageing [ 1 ]. Nevertheless, even if a diagnosis of depression is established, inappropriate treatment can occur [ 2 ]. Beers criteria are the most widely screening tools used to detect inappropriate prescription of drugs in people aged 65 years or more [ 3 ]. Since 2010, attempts to adapt the Beers' criteria have been made in Europe [ 4 , 5 ]. Tricyclic drugs are the ADs to be always avoided in the elderly, owing to their anticholinergic side effects, such as cognitive impairment, delirium, urinary retention and falls [ 3 ]. Selective sero…

Malemedicine.medical_specialtySocio-culturaleInappropriate Prescribing-Potentially inappropriate medication olderPractice Patternsdepression hospitalized patients drugselderlydrugsantidepressivi anzianoPolypharmacy | Inappropriate Prescribing | Medications PIMsantidepressant agent escitalopram paroxetineInternal MedicinemedicineHospital dischargeolderEscitalopramHumansLS4_4Medical prescriptionPractice Patterns Physicians'Depression (differential diagnoses)AgedPolypharmacySertralinePhysicians'antidepressantbusiness.industryTrazodonehospitalized patientsAntidepressive AgentsHospitalizationAcute Disease; Aged; Antidepressive Agents; Female; Humans; Inappropriate Prescribing; Italy; Male; Practice Patterns Physicians'; Hospitalizationantidepressants; elderlyItalyantidepressantsEmergency medicinedepressionAcute DiseasePolypharmacy Inappropriate Prescribing Medications PIMDeliriumFemalePotentially inappropriate medicationmedicine.symptombusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases. A Consensus Document by the Italian Society …

2021

Hypertension is a major contributor to fatal/nonfatal cardiovascular diseases, and timely identification and appropriate management of factors affecting hypertension and its control are mandatory public health issues. By inducing neurohormonal alterations and metabolic impairment, sleep disorders have an impact on a variety of cardiovascular risk factors, including hypertension, and ultimately increase the risk of cardiovascular events. There is evidence that qualitative and quantitative sleep disorders are associated with resistant hypertension and with impaired circadian blood pressure variations. However, sleep disturbances are often unrecognized, or heterogeneity exists in their managem…

0301 basic medicinemedicine.medical_treatmentSleep disorders.Comorbidity0302 clinical medicineCardiovascular DiseaseSleep Initiation and Maintenance DisordersInsomniaContinuous positive airway pressureSleep Apnea ObstructiveContinuous Positive Airway Pressureblood pressureHeart Disease Risk FactorPrognosisSleep in non-human animalsCircadian RhythmAntihypertensive AgentCardiovascular Diseasessleep disordersmedicine.symptomCardiology and Cardiovascular MedicineRisk assessmentHumancardiovascular riskmedicine.medical_specialtyConsensusSleep ApneahypertensionPrognosiConsensuRisk Assessment03 medical and health sciencesTherapeutic approachInternal MedicinemedicineHumansHealthy LifestyleIntensive care medicineConsensus DocumentAntihypertensive AgentsBlood pressure; Cardiovascular risk; Hypertension; Sleep disorders; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Comorbidity; Consensus; Healthy Lifestyle; Heart Disease Risk Factors; Humans; Hypertension; Prognosis; Risk Assessment; Risk Reduction Behavior; Sleep Apnea Obstructive; Sleep Initiation and Maintenance Disorders; Continuous Positive Airway Pressure; SleepSleep disorderbusiness.industryObstructivePublic healthmedicine.diseaseComorbidity030104 developmental biologyBlood pressureHeart Disease Risk Factorsblood pressure; cardiovascular risk; hypertension; sleep disordersbusinessSleepRisk Reduction Behavior030217 neurology & neurosurgery
researchProduct

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

2017

Abstract Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major…

0301 basic medicineApolipoprotein ECandidate geneSettore MED/09 - Medicina InternaDatabases FactualApolipoprotein BDNA Mutational AnalysisFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityPCSK90302 clinical medicineRisk FactorsReceptorsGeneticsHomozygoteAutosomal dominant traitPathogenic variantsGeneral MedicinePrognosisAPOB; Familial hypercholesterolemia; LDLR; PCSK9; Pathogenic variantsCholesterolPhenotypeItalyAutosomal Recessive HypercholesterolemiaApolipoprotein B-100lipids (amino acids peptides and proteins)Proprotein Convertase 9APOBCardiology and Cardiovascular MedicinePreliminary DataGenetic MarkersFamilial hypercholesterolemiaLDLRPCSK9APOBPathogenic variantsHeterozygoteFamilial hypercholesterolemiaBiologyPathogenic variantLDLHyperlipoproteinemia Type II03 medical and health sciencesDatabasesmedicineInternal MedicineHumansAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Internal Medicine; Cardiology and Cardiovascular MedicineGenetic Predisposition to DiseaseFactualPCSK9Settore MED/13 - ENDOCRINOLOGIAAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Cardiology and Cardiovascular Medicine; Internal Medicinemedicine.diseaseAtherosclerosis030104 developmental biologyLDLRReceptors LDLMutationbiology.proteinAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Apolipoprotein B-100; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Preliminary Data; Prognosis; Proprotein Convertase 9; Receptors LDL; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine
researchProduct

Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register

2019

Background: The RePoSi study has provided data on comorbidities, polypharmacy, and sex dimorphism in hospitalised elderly patients. Methods: We retrospectively analysed data collected from the 2010, 2012, 2014, and 2016 data sets of the RePoSi register. The aim of this study was to explore the sex-differences and to validate the multivariate model in the entire dataset with an expanded follow-up at 1 year. Results: Among 4714 patients, 51% were women and 49% were men. The disease distribution showed that diabetes, coronary artery disease, chronic obstructive pulmonary disease, chronic kidney disease, and malignancy were more frequent in men but that hypertension, anaemia, osteoarthritis, de…

medicine.medical_specialtyMultivariate analysislcsh:MedicineSocio-culturaleDisease030204 cardiovascular system & hematologyelderlyArticleCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineMedicine030212 general & internal medicineDepression (differential diagnoses)Polypharmacybusiness.industrylcsh:RGeneral Medicinemedicine.diseaseComorbidityelderly sex profiles disease distribution in-hospital mortality 3-month mortality 1-year mortalityMood disordersdisease distribution1-year mortality3-month mortalitysex profilesbusiness1-year mortality; 3-month mortality; disease distribution; elderly; in-hospital mortality; sex profilesKidney diseasein-hospital mortality
researchProduct

Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry

2020

Currently, chronic obstructive pulmonary disease (COPD) represents the fourth cause of death worldwide with significant economic burden. Comorbidities increase in number and severity with age and are identified as important determinants that influence the prognosis. In this observational study, we retrospectively analyzed data collected from the RePoSI register. We aimed to investigate comorbidities and outcomes in a cohort of hospitalized elderly patients with the clinical diagnosis of COPD. Socio-demographic, clinical characteristics and laboratory findings were considered. The association between variables and in-hospital, 3-month and 1-year follow-up were analyzed. Among 4696 in-patient…

Malemedicine.medical_specialtyChronic ObstructiveCirrhosisSocio-culturaleComorbidity030204 cardiovascular system & hematologycomorbiditieselderlyPulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicine80 and overCOPDHumans030212 general & internal medicineLS4_4RegistriesHospital MortalityCOPD comorbidities elderly internal medicine in-hospital mortality.Depression (differential diagnoses)Cause of deathAgedRetrospective Studies1-year mortality; 3-month mortality; COPD; comorbidities; elderly; internal medicine; in-hospital mortalityAged 80 and overCOPDbusiness.industry1-year mortality; 3-month mortality; COPD comorbidities elderly internal medicine in-hospital mortalitymedicine.diseaseIm - Original1-year mortality; 3-month mortality; COPD comorbidities elderly internal medicine in-hospital mortality; Aged; Aged 80 and over; Comorbidity; Female; Humans; Internal Medicine; Male; Pulmonary Disease Chronic Obstructive; Registries; Retrospective Studies; Hospital Mortalityinternal medicineClinical diagnosisCohortEmergency Medicine1-year mortality3-month mortalityCOPD comorbidities elderly internal medicine in-hospital mortality1-year mortality 3-month mortality COPD comorbidities elderly internal medicine in-hospital mortality.Observational studyFemalebusiness1 year mortalityin-hospital mortality
researchProduct

Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register

2018

As a consequence of population aging, we have witnessed in internal medicine hospital wards a progressive shift from a population of in-patients relatively young and mainly affected by a single ailment to one of ever older and more and more complex patients with multiple chronic diseases, followed as out-patients by many different specialists with poor integration and inevitably treated with multiple medications. Polypharmacy (defined as the chronic intake of five or more drugs) is associated with increased risks of drug-drug interactions and related adverse effects, prescription and intake errors, poor compliance, re-hospitalization and mortality. With this background, the Italian Society …

Malemedicine.medical_specialtyPopulation ageingDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; PolypharmacyPopulationSocio-culturale030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineDeprescribingRisk Factors80 and overDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; Polypharmacy; Internal Medicine; Emergency MedicineInternal MedicinemedicineDeprescribing Inappropriate prescription Medication reconciliation Multimorbidity PolypharmacyHumansMultimorbidityRegistries030212 general & internal medicineMedical prescriptionAdverse effecteducationAgedAged 80 and overPolypharmacyGeriatricseducation.field_of_studybusiness.industryMultimorbidityPatient DischargeHospitalizationDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; Polypharmacy; Aged; Aged 80 and over; Female; Geriatrics; Hospitalization; Humans; Italy; Male; Multimorbidity; Patient Discharge; Registries; Risk Factors; PolypharmacyItalyGeriatricsFamily medicinePolypharmacyEmergency MedicineMedication reconciliationFemaleDeprescribingbusinessDeprescribing; Inappropriate prescription; Medication reconciliation; Multimorbidity; Polypharmacy;Inappropriate prescriptionInternal and Emergency Medicine
researchProduct

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)

2017

Background and aims: Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network). Methods: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationw…

0301 basic medicineCandidate geneGenetic testingSettore MED/09 - Medicina InternaDatabases FactualDNA Mutational AnalysisDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematology0302 clinical medicineDyslipidemias; Genetic testing; National network; Internal Medicine; Cardiology and Cardiovascular MedicineRisk FactorsProspective StudiesProgram DevelopmentProspective cohort studymedicine.diagnostic_testGeneral MedicinePrognosisCholesterolPhenotypeItalyCardiology and Cardiovascular MedicineGenetic Markersmedicine.medical_specialtyNational networkDyslipidemias; Genetic testing; National networkMEDLINEHyperlipoproteinemia Type II03 medical and health sciencesDatabasesInternal medicinemedicineInternal MedicineHumansGenetic Predisposition to DiseaseFactualGenetic testingRetrospective StudiesDyslipidemiasbusiness.industrySettore MED/13 - ENDOCRINOLOGIARetrospective cohort studymedicine.diseaseAtherosclerosisDyslipidemias; Genetic testing; National network; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Prognosis; Program Development; Prospective Studies; Retrospective Studies; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine030104 developmental biologyEndocrinologyDyslipidemiaGenetic markerMutationbusiness
researchProduct